What SureNano Science does

SureNano Science is a Vancouver, BC-based life sciences and specialty chemicals company listed on the CSE under the ticker SURE (OTCQB: SURNF) since December 2021. The company has historically operated a surfactant and nano-emulsion business built around its proprietary SureNano Emulsifier technology, with FDA GRAS designation and Health Canada approvals supporting applications in food, beverage, and cosmetics. In early 2026 the company executed a strategic pivot into pharmaceutical development through the acquisition of GlucaPharm Inc., which holds exclusive development rights to GEP-44, a GLP-1 receptor agonist peptide originally licensed from Syracuse University. GEP-44 is in preclinical development, is advancing through FDA IND-enabling studies with LabCorp, and carries patent protection extending into 2042. The company is also pursuing adjacent opportunities including Ibogaine IP licensing. The company operates with a headcount in the 11–50 range and a market capitalization of approximately $9.8 million on 42 million-plus shares outstanding.

The business model spans two revenue streams with very different profiles. The legacy surfactant business generates cash via direct product sales — Emerald Scientific is the only named customer — and through narrow exclusive regional licensing arrangements covering Canada, Oklahoma, and Colorado. The pharmaceutical business is currently pre-revenue; GEP-44 and the Ibogaine program must clear IND-enabling studies, clinical trials (with planned execution in Australia), and regulatory approval before any product-related revenue can be realized, which places meaningful commercialization several years out at minimum. The company raised approximately $1.495M across two private placements in late 2025 to fund the pivot and early development, and has assembled a leadership team that includes CSO Dr. Nihar Pandey, scientific founders Dr. Doyle and Dr. Billing, and board appointee Doug Bachman.

SureNano serves two distinct customer sets: B2B specialty chemicals buyers in food, beverage, and cosmetics manufacturing, and — prospectively, post-approval — pharmaceutical partners, payers, and patients in the metabolic disease treatment market. The current revenue base is small and concentrated, the pharmaceutical pipeline is preclinical, and the company's near-term trajectory depends on continued capital formation and successful execution of the GEP-44 regulatory pathway rather than on the existing surfactant book of business.

Name

SureNano Science

Legal name

SureNano Science Ltd.

Website

https://surenano.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

SureNano Science is a Vancouver-based life sciences company developing the GLP-1 peptide therapeutic GEP-44 (via GlucaPharm acquisition) alongside a legacy nano-emulsion surfactant business serving food, beverage, and cosmetics customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical & Drug Delivery Systems

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

Keywords

• Nanoemulsion surfactants
• Drug delivery systems
• GLP-1 therapeutics
• Metabolic disease peptides
• Food grade emulsifiers

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Surfactant Product Sales: Sale and distribution of SureNano surfactant, a ready-to-mix food grade compound for nanoemulsions. Exclusive licensing agreements in Canada, Oklahoma, and Colorado generate product revenue.
2. Pharmaceutical Licensing and Royalties: Future revenue from licensing GEP-44 drug candidate to pharmaceutical partners. Revenue to be generated upon FDA approval and commercialization of metabolic therapeutics.
3. Private Placement Financing: Capital raises through private placements to fund operations and development. December 2025 closing of $1,250,000 through issuance of units comprising common shares and warrants.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

SureNano Science Ltd. is a publicly traded life sciences company operating two integrated lines: (1) a commercialized nanoemulsion surfactant platform — the FDA GRAS-approved, Health Canada-compliant SureNano Emulsifier and the in-development SureNano Powder — distributed through exclusive licenses in Canada and select US states; and (2) a pharmaceutical pipeline via its wholly owned subsidiary GlucaPharm Inc., anchored by GEP-44, a patented triple-agonist peptide (GLP-1 + Y1 + Y2) licensed from Syracuse University for obesity and metabolic disease, currently in FDA IND-enabling toxicology studies.

Product overview

SureNano Science Ltd. operates as a dual business entity: (1) A nanotechnology-enabled surfactant and delivery platform consisting of the SureNano™ Emulsifier (FDA GRAS-approved, Health Canada-approved liquid nanoemulsion) and SureNano™ Powder (in development); and (2) A pharmaceutical development pipeline anchored by the acquired subsidiary GlucaPharm Inc. and its lead asset GEP-44, a patented triple-agonist peptide therapeutic for obesity and metabolic disease. The company is transitioning from an enabling-technology company focused on drug delivery enhancement toward becoming a near-term pharmaceutical value creator in the GLP-1 metabolic market.

Differentiator

Problem solved

Functional benefit

Brands

• GlucaPharm: Subsidiary brand focused on developing next-generation GLP-1 pharmaceutical compounds including GEP-44 for obesity and metabolic disease.
• SureNano™ Emulsifier
• SureNano™ Surfactant

Products and services

• SureNano™ Emulsifier A 100% plant-derived, ready-to-mix food-grade stabilizing formula that delivers high-performance nanoemulsions for beverages, topical products, and consumables; maximizes bioavailability, clarity, and taste. Approved by FDA (GRAS) and Health Canada. Manufactured by Caldic under GFSI SQF, CFIA, and GMP quality systems. Distributed exclusively in Canada, Oklahoma (USA), and Colorado (USA).
• SureNano™ Powder A powder-format nanoemulsion product in development that extends the SureNano surfactant line into dry-blend applications. Developed under a joint venture with 1150641 B.C. Ltd. with each joint venturer contributing $30,000 and exclusive license rights for Canada, Oklahoma, and Colorado.
• GEP-44 Triple Agonist Peptide Therapeutic A patented monomeric peptide that acts as a triple agonist on GLP-1 and Peptide YY (PYY) receptors Y1 and Y2, intended for treatment of obesity, Type 2 diabetes, and metabolic disease. Demonstrated approximately 15% body weight reduction and 39% food intake reduction in preclinical studies with no GI side effects. Designed for oral, sublingual, or nasal non-injectable delivery. Patent-protected through 2042 (U.S. Patent Application 20220204581A1), exclusively licensed from Syracuse University.

Quantifiable outcome

• ~15% body weight reduction in preclinical obese rat studies vs ~9% for liraglutide
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• LabCorpcoreImplementation/ SI/ Consulting Partner · 24 April 2026Collaboration with premier global CRO LabCorp for GLP-compliant toxicology and pharmacology studies for GEP-44. Studies covering rodents and non-rodent primates to determine MTD, safety margins, and biomarkers for first-in-human studies.
• Academic Institutions and Research Groups (Ibogaine)minorStrategic or Co-development Partner · 24 April 2026Early-stage discussions to license or acquire IP related to synthesis, formulation, and delivery of Ibogaine and next-generation analogues for mental health and addiction treatment.
• Investor Brand Network (IBN)minorGTM or Marketing Partner · 23 April 2026Six-month corporate communication and awareness strategy leveraging IBN's syndication network of over 5,000 media outlets, newsletters, social channels, and wire services. Quarterly cash consideration USD $29,000.
• The Market Link (iHub)minorGTM or Marketing Partner · 23 April 2026Enhanced news release distribution with news blast and forum boost advertising campaign. One-time cash fee of USD $10,000 plus applicable taxes.
• TDM Financial (Emerging Growth, LLC)minorGTM or Marketing Partner · 22 April 2026Six-month investor outreach and awareness campaign. Distribution of sponsored content across leading financial websites, social platforms (X, Reddit, TikTok, LinkedIn), and multimedia content production. Total cash consideration USD $26,667.
• BTV (Milky Way Marketing Inc. and Blue Sun Productions Inc.)minorGTM or Marketing Partner · 23 February 2026Marketing and broadcast package including 30-second TV spot, TV ad spots, 40 BNN Bloomberg broadcasts, stock ticker ad, and newsletter eblast. Cash fee of $22,300 plus GST.
• Emerald ScientificcoreChannel Partner/ Reseller/ Distributor · 1 January 2020Emerald Scientific launched the SureNano Emulsifier product in 2020, developed over two years. Product is 100% plant-derived stabilizing formula for high-performance nanoemulsions.
• Syracuse UniversitycoreTechnology or IntegrationSyracuse University researchers, led by Dr. Robert Doyle, discovered GEP-44 peptide technology. SureNano acquired GlucaPharm which holds exclusive license from Syracuse University for GEP-44 development. Research supported by NIH and other US entities.
• 1150641 B.C. Ltd.coreStrategic or Co-development PartnerJoint venture partner for development and marketing of SureNano powder nanoemulsion product. Each joint venturer contributed $30,000. Exclusive license agreements for Canada, Oklahoma, and Colorado.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Viking Therapeutics: Clinical-stage biotech developing peptide therapeutics for metabolic disease, including VK2735 (a dual GLP-1/GIP receptor agonist) for obesity. Highly comparable to SureNano/GlucaPharm as a small-cap, differentiated-mechanism GLP-1 developer pursuing the same end-market.
• Structure Therapeutics: Clinical-stage company developing oral small-molecule GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and type 2 diabetes. Closely comparable to SureNano's GEP-44 strategy of pursuing a differentiated, non-injectable GLP-1 mechanism to compete with injectable incumbents.
• Altimmune: Clinical-stage biopharmaceutical company developing peptide therapeutics for metabolic disease, including pemvidutide, a GLP-1/glucagon dual agonist for obesity. Comparable as a small-cap peptide metabolic disease developer with similar clinical-stage positioning to GlucaPharm.
• Zealand Pharma: Denmark-based peptide therapeutics company developing multiple peptide candidates for metabolic disease and obesity, with a strong focus on differentiated mechanisms and non-injectable delivery. Directly comparable to GEP-44's peptide-mechanism, metabolic-disease focus.

Broad incumbents

• Eli Lilly: Major pharmaceutical company and current market leader in the GLP-1 space with Mounjaro/Zepbound (tirzepatide, a dual GIP/GLP-1 agonist) and an extensive next-generation obesity/diabetes pipeline. Defines the competitive environment in which SureNano/GlucaPharm must compete.
• Novo Nordisk: Global leader in GLP-1 therapy with Ozempic and Wegovy (semaglutide) plus an oral GLP-1 (Rybelsus) and deep next-gen pipeline. Sets the efficacy, tolerability, and commercial benchmarks that any GEP-44 must meet or exceed to succeed.
• Croda International: Global specialty chemicals company producing high-performance surfactants, formulation ingredients, and delivery systems for personal care, food, and life sciences markets. Comparable to SureNano's legacy nanoemulsion/surfactant business on the non-pharma side.

Emerging players

• Lexicon Pharmaceuticals: Small-cap clinical-stage biotech focused on small-molecule drug discovery for metabolic and neuropathic disease. Comparable as an emerging player with limited resources pursuing differentiated metabolic-disease mechanisms.
• Soleno Therapeutics: Small-cap clinical-stage company developing therapeutics for rare metabolic disorders (e.g., Prader-Willi syndrome). Comparable profile to GlucaPharm as a micro-cap clinical-stage metabolic-disease developer with concentrated single-asset risk.

Others

• Emerald Scientific: Distributor and channel partner that launched the SureNano Emulsifier product in 2020 and is a select customer for SureNano's surfactant line. Listed as an ecosystem/distribution peer rather than a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SureNano Science